A Comparison of SYMBICORT® pMDI With Budesonide HFA pMDI in African American Subjects With Asthma.
Recruiting in Palo Alto (17 mi)
+120 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: AstraZeneca
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine the effectiveness and safety of SYMBICORT® pMDI (a medication approved by the Food and Drug Administration, FDA) in the African American population.
Eligibility Criteria
Inclusion Criteria
Male or Female, African American (self-reported), ≥12 years of age
Moderate to severe asthma requiring treatment with an inhaled corticosteroid
Diagnosis of asthma for at least 6 months
Treatment Details
Interventions
- Budesonide/formoterol (SYMBICORT) pMDI (Corticosteroid)
- Budesonide HFA pMDI (Corticosteroid)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: SymbicortExperimental Treatment1 Intervention
Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
Group II: BudesonideExperimental Treatment1 Intervention
Budesonide HFA pMDI 160 ug x 2 actuations BID
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Research SiteBlackwood, NJ
Research SiteSpartanburg, SC
Research SiteBethesda, MD
Research SiteNewburgh, NY
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
AstraZenecaLead Sponsor